Immunic Taps Biogen Veteran Bonney as Chair to Navigate Critical MS Drug Milestones
Event summary
- Immunic appoints Michael W. Bonney as Chair of the Board, effective May 16, 2026.
- Bonney brings 30+ years of biopharmaceutical experience, including key roles in Biogen's Avonex® launch and Cubist's $9.5B acquisition by Merck.
- Bonney's appointment comes ahead of phase 3 ENSURE trial readouts for vidofludimus calcium in relapsing MS, expected by year-end 2026.
- Simona Skerjanec transitions from Interim Chair to Board member.
- Immunic's lead candidate, vidofludimus calcium, combines neuroprotective, anti-inflammatory, and antiviral effects.
The big picture
Immunic's appointment of Michael W. Bonney as Chair underscores the strategic importance of its upcoming clinical milestones for vidofludimus calcium, a potential differentiated therapy for multiple sclerosis. Bonney's deep experience in commercializing neurology drugs and orchestrating high-value exits positions Immunic to navigate the complex transition from late-stage development to market readiness. The move reflects broader industry trends where biotech companies leverage seasoned executives to bridge the gap between innovation and commercial success.
What we're watching
- Clinical Trial Outcomes
- How the phase 3 ENSURE trial results for vidofludimus calcium will impact Immunic's regulatory path and commercial strategy.
- Commercialization Readiness
- Whether Bonney's experience can accelerate Immunic's transition to a fully integrated commercial-stage company.
- Pipeline Expansion
- The pace at which Immunic advances its earlier-stage programs (IMU-856, IMU-381) to diversify its therapeutic platform.
Related topics